Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma

Terminated

Conditions: B-Cell Non-Hodgkin Lymphoma
Absence of Signs or Symptoms
Digestive System Signs and Symptoms
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Indolent Adult Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Colonoscopy
Procedure: Colposcopic Biopsy
Drug: Idelalisib
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Procedure: Physical Examination
Procedure: Sigmoidoscopy

First Posted Date: 2016-10-10

Last Posted Date: 2021-07-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT02928510

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

Early Phase 1

Completed

Conditions: Autoimmune Disease
Crohn Disease
Rheumatoid Arthritis
Inflammatory Disorder
Systemic Lupus Erythematosus
Takayasu Arteritis

Interventions: Procedure: Computed Tomography
Radiation: Fluorine F 18 Clofarabine
Procedure: Positron Emission Tomography

First Posted Date: 2016-10-05

Last Posted Date: 2020-09-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT02925351

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

Withdrawn

Conditions: Glioblastoma
Glioma

Interventions: Procedure: Computed Tomography
Radiation: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography

First Posted Date: 2016-09-29

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT02919332

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Not Applicable

Recruiting

Conditions: Glioblastoma

Interventions: Procedure: Computed Tomography
Radiation: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography

First Posted Date: 2016-09-16

Last Posted Date: 2024-11-22

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT02902757

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

Terminated

Conditions: Malignant Neoplasm

Interventions: Procedure: Computed Tomography
Radiation: Fluorine F 18 Clofarabine
Procedure: Positron Emission Tomography

First Posted Date: 2016-09-05

Last Posted Date: 2020-08-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT02888301

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IIIB Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-08-26

Last Posted Date: 2021-07-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT02879994

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Hormone-Resistant Prostate Cancer
Stage IV Prostate Cancer
Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Trametinib

First Posted Date: 2016-08-26

Last Posted Date: 2023-05-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 14

Registration Number: NCT02881242

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Biological: Nivolumab

First Posted Date: 2016-08-26

Last Posted Date: 2022-08-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT02880020

Locations: 🇺🇸
Rachel Andes, Los Angeles, California, United States

Project Connect Online: An Internet-based Intervention for Women With Breast Cancer

Not Applicable

Completed

Conditions: Breast Neoplasms

Interventions: Behavioral: Project Connect Online
Behavioral: PCO PLUS

First Posted Date: 2016-08-15

Last Posted Date: 2020-10-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 33

Registration Number: NCT02866994

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Not Applicable

Withdrawn

Conditions: Pancreatic Cancer

Interventions: Drug: FG-3019

First Posted Date: 2016-08-01

Last Posted Date: 2016-10-07

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT02851381

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy